overriding imatinib resistance novel abl kinase inhibitor 
resistance abl kinase inhibitor imatinib sti571 gleevec chronic myeloid leukemia cml occurs selection tumor cells harboring bcr-abl kinase domain point mutations interfere drug binding crystallographic studies predict imatinib-resistant mutants remain sensitive inhibitors bind abl less stringent conformational requirements bms orally bioavailable abl kinase inhibitor two-log increased potency relative imatinib retains activity imatinib-resistant bcr-abl mutants bms prolongs survival mice bcr-abl-driven disease inhibits proliferation bcr-abl-positive bone marrow progenitor cells patients imatinib-sensitive imatinib-resistant cml data illustrate molecular insight kinase inhibitor resistance can guide design second-generation targeted therapies 
